In line with our previous work to look for effective analogs of androgen receptor blockers [21], the current study aims to develop hybrid pharmacophores based on a combination of different pharmacophoric moieties, namely, 2-thioxoimidazolidin-4-one and pyrazole scaffolds that exist in FDA-approved prostate cancer drugs as enzalutamide and darolutamide; respectively (Figure 2). Here, AR is linked to prostate carcinoma.